Ophthalmology Times10h
FDA accepts new drug application for low-dose atropine from Sydnexis
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Ophthalmology Times12h
Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment
Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...